Global Cervical Dystonia Market - 2023-2030

Overview

Cervical Dystonia is a distinct condition that involves the head and neck. Cervical dystonia elicits extreme muscle contractions in the neck. These muscle contractions induce involuntary actions and uncomfortable positions of the head, neck, and occasionally shoulders. Cervical Dystonia generally referred to as spasmodic torticollis, is a distinct kind of focal dystonia that impacts the muscles of the neck.

It manifest in different types as torticollis, laterocollis, anterocollis and retrocollis. As the muscles of the neck are hyperactive, the individual's stance may be impacted inducing pain and stiffness in other muscles not impacted by the dystonia. For the majority of individuals, no reason is discovered. Nevertheless, it is typically assumed that cervical dystonia is linked to difficulty with the functioning and links of various regions of the brain such as the basal ganglia and cerebellum. Presently there is no known cure, but there are therapies that aid with the symptoms are available.

The growing cases of cervical dystonia, market developments including mergers, acquisitions, products introductions, growing awareness among other factors are expected to boost the global cervical dystonia market growth in the forecast period. Further, the growing research activities, technological advancements and with fundings in cervical dystonia are also expected to contribute to the global market growth in the forecast period.

Dynamics

Increasing Research Activities

The increasing research activities are expected to boost the global market growth during the forecast period. For instance, Daewoong Pharmaceutical, a bioengineering corporation in South Korea, declared that its Nabota, a botulinum toxin product underway the U.S. Food and Drug Administration (FDA) approved clinical trials to demonstrate the effectiveness of Nabota in migraine and cervical dystonia. Moreover, according to Clinical Trials.gov presently one interventional investigation is actively evaluating the first line of treatment for cervical dystonia individuals with botulinum toxin injections, with some patients receiving this treatment long-term experiencing a short duration of relief.

Further, according to the reports from the University of South Florida in Tampa presented at the American Academy of Neurology's (AAN) annual meeting, a new botulinum toxin formulation held cervical dystonia signs at bay for a reliable 16 weeks in the majority of individuals treated in a manufacturer-sponsored phase III trial, Median time to preserve at least 80% of the peak therapy effect was 20-24 weeks, based on the dosage of daxibotulinumtoxinA (Daxi for short) administered, and around two-thirds of individuals still maintained at least 80% of the full effect at week 16.

Increasing Fundings

The increasing funding from distinct authorities and associations to advance dystonia therapies is also expected to boost the global market growth in the forecast period. For instance, the Dystonia Network of Australia Inc.'s foremost purpose has been to contribute to the dystonia study, for instnace, in 2021 DNA raised a total of $4700 funds for dystonia study with movements such as a walkathon, morning tea, and plant sale.

Moreover, a study to enhance the detection and therapy of the movement disorder, dystonia, has drawn $100,000 in funding from the WA Department of Health for an assignment guided by Perron Institute and Fiona Stanley Hospital. The Center for Health+Technology (CHeT) obtained a $2.9 million grant from the U.S. Department of Defense to design novel result criteria for usage in therapeutic investigations concerning a spectrum of chronic conditions. These tools are expected to deliver a platform for individuals to deliver an understanding of the merit of encouraging therapies in clinical trials.

The investigation, entitled Longitudinal Endpoint Optimization to Provide Assessments of Relevant Drugs (LEOPARD), is expected to advance clinical study readiness by designing research tools for mitochondrial disorder, cardiomyopathy, rheumatoid arthritis, and dystonia. There are presently few practical remedies obtainable for these four life-altering, chronic conditions. The investigation is being supported by the Defense Department's Peer Reviewed Medical Research Program, which was designed to enhance the well-being and operation of military personnel, their families, and civilians while enhancing U.S. combat readiness and performance.

Low Prevalence of the Condition

The low prevalence of cervical dystonia is expected to hamper the global market growth during the forecast period, as low prevalence restricts the research and lack of condition understanding. According to the National Organization for Rare Disorders, Inc., Cervical dystonia, also comprehended as spasmodic torticollis, is an infrequent neurological condition that develops in the brain.

The NIH estimated prevalence ranges from 5 to 30 cases per 100,000 individuals. The NIH estimated prevalence is 3-9 cervical dystonia (CD) cases per 100,000 population. Also, the prevalence of early-onset dystonia (<20 years) is estimated to be between 0.3 and 5 cases per 100,000, whereas the prevalence of adult-onset (>20 years) dystonia is between 0.3 and 732 cases per 100,000.

Neurologist Workforce Shortage

The extensive neurologist workforce gaps are expected to hamper the global market growth during the forecast. For instance, the data published by the Association of British Neurologists (ABN) indicates that the UK's workforce of adviser neurologists is extremely down than might be anticipated. In comparison to France and Germany, the UK workforce is largely inferior, even in London and the neighboring places where ratios of patient to adviser are sounder.

Thus, individuals with dystonia usually encounter a lack of medical professionals with the professional training to comprehend and treat dystonia. This deficiency indicates individuals are waiting for extended periods to obtain a diagnosis, there are very few clinical staff injecting BoNT, and it takes too long to assemble new trained injectors. Typically, there are long waiting periods for treatment and up to 40% of people with CD discontinue long-term BoNT therapy following a sensed insufficiency of efficacy.

Segment Analysis

The global cervical dystonia market is segmented based on type, therapy type, end-user and region.

Injections of Botulinum Toxin (Botox) Therapy Type Expected to Dominate Market

There is no specific treatment for cervical dystonia, but manifestations can be controlled utilizing a combination of therapies. The symptoms of cervical dystonia (CD) include uncontrollable muscle spasms in the neck which induce awkward poses, discomfort, and discomfort. Following detection, Botulinum NeuroToxin (BoNT) therapy is the acknowledged benchmark of care in individuals with CD. When the dystonic muscles are injected precisely the comfort and quality of life can be considerably improved.

There are currently four brands of Botulinum toxin that have been authorized by the Food and Drug Administration (FDA) for the therapy of individuals with cervical dystonia. There are three brands of botulinum toxin serotype A, enclosing onabotulinumtoxinA (BOTOX, Allergan Inc.) abobotulinumtoxinA (Dysport, Tercica Inc), and incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals). There is one formulation of botulinum toxin type B, rimabotulinumtoxinB (Myobloc, Solstice, US World Meds).

Further, the new product approvals in this segment are contributing to the segment growth in the forecast period. For instance, in August 2023, Revance Therapeutics, Inc. obtained extended approval from the United States (U.S.) Food and Drug Administration (FDA) for DAXXIFY (DaxibotulinumtoxinA-lanm) injection for cervical dystonia treatment in adults. DAXXIFY, powered by Peptide Exchange Technology, was earlier authorized by the FDA for the temporary enhancement of glabellar lines (frown lines) in adults in September 2022.

Geographical Penetration

Increasing Market Developments in North America

The growing prevalence of cervical dystonia in North America is expected to boost the regional market growth in the forecast period. For instance, cervical dystonia impacts individuals of all ethnic backgrounds. The exact incidence or prevalence of cervical dystonia in the general population is unknown but is estimated to be about 60,000 people in the United States.

American Association of Neurological Surgeons, as many as 250,000 people in the United States have dystonia, making it the third most common movement disorder behind essential tremor and Parkinson's disease. The presence of key market players holding the majority of the global market share along with distinct associations supporting research activities are also contributing to the regional market growth in the forecast period. For instance, the Michael J. Fox Foundation supports research to develop better treatments for the 500,000 individuals in North America living with dystonia.

COVID-19 Impact Analysis

During the COVID-19 pandemic, elective and routine examinations and operations were postponed or discontinued because of redirecting aids to additional emergent therapy for extremely sick individuals and to avert the spread and contraction of COVID-19. Further, the workforce was pulled narrow, and healthcare structures witnessed growing turnover rates for full-time and agreement workers, which pushed the system and decreased the capacity to deliver clinical assistance.

One of the losses of these shifts was rare neurological disorders, which have been assisted less frequently all over the globe since the pandemic. Whether considered standard or emergent, the deferral of neurological disorders induced downstream consequences, including the delay in diagnosis and beginning treatment for cervical dystonia inducing a more raised drop in quality of life.

By Type

• Torticollis
• Laterocollis
• Anterocollis
• Retrocollis
• Others

By Therapy Type

• Drug Therapy
  • Anticholinergics
  • Benzodiazepines
  • Muscle Relaxant
  • Tetrabenazine
  • Others

• Botox Injections
• Others

By End-User

• Hospitals
• Specialty Clinics
• Academic Research Centers
• Other

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In August 2023, Revance Therapeutics, Inc., the United States (U.S.) Food and Drug Administration (FDA) has authorized the first therapeutic indication for DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for cervical dystonia therapy in adults.
• In September 2022, AEON Biopharma informed positive topline outcomes from the phase-2 clinical investigation of ABP-450 (prabotulinumtoxinA) in treatment of cervical dystonia in adults.

Competitive Landscape

The major global players in the market include Allergan Inc., Boston Scientific Corporation, Tercica Inc, US World Meds, Merz Pharmaceuticals, AEON Biopharma, Revance Therapeutics, Inc., Galderma SA, Ipsen Pharma, and AbbVie Inc. among others.

Why Purchase the Report?

• To visualize the global cervical dystonia market segmentation based on type, therapy type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cervical dystonia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.

The global cervical dystonia market report would provide approximately 61 tables, 65 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies